Novo Nordisk to Halve Ozempic and Wegovy Prices in the U.S. Starting 2027

Feb 24, 2026

Novo Nordisk has announced it will reduce the list prices of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% in the United States. The new pricing will take effect in January 2027.

After the reduction, both medications will have a list price of $675 per month. Novo Nordisk aims to make these treatments more affordable, especially for people with insurance plans that base out-of-pocket expenses on the list price. This includes individuals with high-deductible health plans or those with co-insurance arrangements.

The company stated that lowering the list prices is meant to help more people access their innovative medicines.

Why is Novo Nordisk lowering the prices of Ozempic and Wegovy?

Novo Nordisk wants to make these drugs more affordable for people whose out-of-pocket costs are tied to the list price, such as those with high-deductible or co-insurance health plans.

When will the price cuts take effect?

The lower prices for Ozempic and Wegovy will start in January 2027.

How much will Ozempic and Wegovy cost after the price cut?

Both drugs will have a list price of $675 per month after the reduction.

Sources
Novo Nordisk will slash the list prices for its popular drugs Wegovy and Ozempic...
WSJ
The reductions will take effect next January, and both Ozempic and Wegovy will list for $675 a month.
Ozempic And Wegovy Prices Will Be Cut Next Year, Drug-Maker Says
Forbes
“The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs,” Jamey Millar, executive vice president of the US oper...
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for in...
CNBC
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more accessible to patients with insurance coverage, particularly people with high-deductible health plans...
Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%
Fox Business
Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, lowering costs to $675 per dose.
Ozempic, Wegovy prices to drop up to 50% as Novo Nordisk's rivalry with Eli Lill...
New York Post
Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by as much as 50%, according to a report.
Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low
24/7 Wall Street
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low.
Ozempic Price War - Novo Nordisk Slashes Prices By 50%
Benzinga
Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday's premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.
Show All Sources
Related Posts
Other News
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett